The Integrated Mutation Profiling of Actionable Cancer Targets (IMPACT) gene profiling assay is a diagnostic test devised by MSK to identify a variety of gene mutations (biomarkers) found in a variety of cancers. It was granted FDA approval last month. By identifying the mutations present in a tumor, clinicians can better treat a patient’s cancer for their exact tumor type. The IMPACT test works by comparing tumor tissue to normal tissue or cells to detect changes in the genetic makeup of the tumor that can direct treatment options.